Updated
Osteoporosis: Asian pipelines and global competitors
As of 2026-11-14, Asian osteoporosis participants include Celltrion, Samsung Bioepis and Henlius, each with a denosumab biosimilar. Their mechanism differs from the global comparators romosozumab and abaloparatide. This page distinguishes antiresorptive and bone-forming pathways and does not present biosimilars as novel mechanisms.
Selected injectable biologics and peptides, not a census of all osteoporosis medicines. Oncology bone-disease presentations are kept separate.
Asian companies
| Asset | Company | Mechanism / route | Stage | Indication | Latest verified record | Sources |
|---|---|---|---|---|---|---|
CT-P41 / STOBOCLO | Celltrion (South Korea) | Anti-RANKL; denosumab biosimilar SC | Approved and launched in the US | High-fracture-risk osteoporosis and other labeled indications | US launch announcement: STOBOCLO references Prolia; the OSENVELT oncology presentation is distinct. | |
SB16 / OSPOMYV / OBODENCE | Samsung Bioepis (South Korea) | Anti-RANKL; denosumab biosimilar SC | Approved in the US / EU | Osteoporosis and other labeled indications | Reported Phase 3 osteoporosis subgroup analyses; not a novel mechanism or new approval announcement. | |
HLX14 / BILDYOS | Henlius / Organon | Anti-RANKL; denosumab biosimilar SC | Approved in North America / Europe; China application under review | Osteoporosis and other indications; BILDYOS presentation | The 2026 interim deck lists approval and filing status; its August cover date is used, not the November upload path. |
Global comparators
| Asset | Company | Mechanism / route | Stage | Indication | Latest verified record | Sources |
|---|---|---|---|---|---|---|
denosumab / Prolia | Amgen | Anti-RANKL antibody; reference product SC | Approved | Osteoporosis and other labeled indications | Q3 global sales were USD 632 million; the company noted multiple biosimilar launches globally. | |
romosozumab / EVENITY | Amgen / UCB | Anti-sclerostin antibody SC | Approved | Postmenopausal osteoporosis at high fracture risk | Q3 filing reports global quarterly EVENITY sales of USD 751 million; a financial event is not new efficacy evidence. | |
abaloparatide / TYMLOS | Radius Health | PTHrP analog SC | Approved in the US | High-fracture-risk postmenopausal women; increased bone density in men | DailyMed label updated on 08-11, including hypersensitivity warnings; this predates the page’s 90-day window. |
Events in the last 90 days
2026-08-17 – 2026-11-14
denosumab / Prolia
Q3 global sales were USD 632 million; the company noted multiple biosimilar launches globally. Primary source
romosozumab / EVENITY
Q3 filing reports global quarterly EVENITY sales of USD 751 million; a financial event is not new efficacy evidence. Primary source
Sources and downloads
- Celltrion US launch — 2025-07-08
- Samsung SB16 osteoporosis subgroup analysis — 2026-04-17
- Samsung SB16 approval listing — Undated
- Henlius interim presentation, pp. 25–26 — 2026-08
- Amgen Q3 2026 results — 2026-11-03
- TYMLOS label — 2026-08-11
Information cutoff 2026-11-14